The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase

Molecular Genetics and Metabolism

Volumn 66, Issue 1, 1999, Pages 24-30

  Ochel, Hans Joachim ^a   Schulte, Theodor W ^a   Nguyen, Phuongmai ^a   Trepel, Jane ^a   Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

FAK; Geldanamycin; hsp90; Proteolysis

Indexed keywords

ANSAMYCIN DERIVATIVE; BENZOQUINONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0032787306     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1998.2774     Document Type: Article

References (46)

1. Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci USA 87:3328-3332, 1990.
2. Reynolds AB, Roesel DJ, Kanner SB, Parsons JT. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol 9:629-638, 1989.
3. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 89:5192-5196, 1992.
4. Hildebrand JD, Schaller MD, Parsons JT. Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. J Cell Biol 123:993-1005, 1993.
5. Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 267:23439-23442, 1992.
6. Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 119:905-912, 1992.
7. Derkinderen P, Toutant M, Burgaya F, Le BM, de Siciliano JCFV, Gelman M, Girault JA. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273:1719-1722, 1996.
8. Kharbanda S, Saleem A, Yuan Z, Emoto Y, Prasad KV, Kufe D. Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mediated association of the focal adhesion kinase pp125FAK and dynamin. Proc Natl Acad Sci USA 92:6132-6136, 1995.
9. Rankin S, Rozengurt E. Platelet-derived growth factor modulation of focal adhesion kinase (p125FAK) and paxillin tyrosine phosphorylation in Swiss 3T3 cells. Bell-shaped dose response and cross-talk with bombesin. J Biol Chem 269:704-710, 1994.
10. Rankin S, Hooshmand RR, Claesson WL, Rozengurt E. Requirement for phosphatidylinositol 3′-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p 125 focal adhesion kinase and paxillin. J Biol Chem 271:7829-7834, 1996.
11. Sinnett SJ, Zachary I, Valverde AM, Rozengurt E. Bombesin stimulation of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, Ca2+ mobilization, and the actin cytoskeleton. J Biol Chem 268:14261-14268, 1993.
12. Whitney GS, Chan PY, Blake J, Cosand WL, Neubauer MG, Aruffo A, Kanner SB. Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK. DNA Cell Biol 12:823-830, 1993.
13. Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA 89:8487-8491, 1992.
14. Furuta Y, Ilic D, Kanazawa S, Takeda N, Yamamoto T, Aizawa S. Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene 11:1989-1995, 1995.
15. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T, Aizawa S. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:530-544, 1995.
16. Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of focal adhesion kinase gene and invasive cancer. Lancet 342: 1024-1025, 1993.
17. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55:2752-2755, 1995.
18. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol 23:1153-1159, 1995.
19. Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 358:690-692, 1992.
20. Akasaka T, Van LR, Yoshinaga IG, Mihm MJ, Byers HR. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 105:104-108, 1995.
21. Frisch SM, Vuori K, Ruoslahti E, Chan HP. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134:793-799, 1996.
22. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442-447, 1970.
23. Uehara Y, Fukazawa H, Murakami Y, Mizuno S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 163:803-809, 1989.
24. Yamaki H, Nakajima M, Seimiya H, Saya H, Sugita M, Tsuruo T. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. J Antibiot (Tokyo) 48:1021-1026, 1995.
25. Whitesell L, Mimnaugh EG, De CB, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src hetero-protein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328, 1994.
26. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 54:2724-2730, 1994.
27. Schulte T, Blagosklonny M, Ingui C, Neckers L. Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588, 1995.
28. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 271: 4974-4977, 1996.
29. Smith D, Whitesell L, Nair S, Chen S, Prapapanich V, Rimerman R. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 15:6804-6812, 1995.
30. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signaling pathway. Mol Cell Biol 16:5839-5845, 1996.
31. Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10:705-712, 1996.
32. lck. Biochemistry 35: 13451-13459, 1996.
33. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N. Herbimycin A induces the 20 S proteasome- and ubiquitin- dependent degradation of receptor tyrosine kinases. J Biol Chem 270:16580-16587, 1995.
34. c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-22801, 1996.
35. Whitesell L, Suthphin P, An W, Schulte T, Blagosklonny M, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14:2809-2816, 1997.
36. Fenteany G, Standaert RF, Lane WAS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731, 1995.
37. Omura S, Fujimoto T, Otoguro K, Matsuzaki K, Moriguchi R, Tanaka H, Sasaki Y, Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells [letter]. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells [letter]. J Antibiot (Tokyo) 44:113-116, 1991.
38. Sasaki T, Kishi M, Saito M, Tanaka T, Higuchi N, Kominami E, Katunuma N, Murachi T. Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathespins. J Enzyme Inhibition 3:195-201, 1990.
39. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature(London) 227:680-685, 1970.
40. Cooray P, Yuan Y, Schoenwaelder SM, Mitchell CA, Salem HH, Jackson SP. Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain. Biochem J 318:41-47, 1996.
41. McGowan EB, Becker E, Detwiler TC. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem Biophys Res Commun 158:432-435, 1989.
42. Wilcox D, Mason RW. Inhibition of cysteine proteinases in lysosomes and whole cells. Biochem J 285:495-502, 1992.
43. Figueiredo-Pereira ME, Banik N, Wilk S. Comparison of the effect of calpain inhibitors on two extralysosomal Proteinases: The multicatalytic proteinase complex and m-calpain. J Neurochem 62:1989-1994, 1994.
44. Li-hui Xu LVO, Sturge GC, Yang X, Liu ET, Craven RJ, Cance WC. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 7:413-418, 1996.
45. Crouch DH, Fincham VJ, Frame MC. Targeted proteolysis of the focal adhesion kinase pp125 FAK during c-MYC-induced apoptosis is suppressed by integrin signalling. Oncogene 12:2689-2696, 1996.
46. Fincham VJ, Wyke JA, Frame MC. v-Src-induced degradation of focal adhesion kinase during morphological transformation of chicken embryo fibroblasts [published erratum appears in Oncogene 11:2185, 1995]. Oncogene 10:2247-2252, 1995.